novo nordisk semaglutide alzheimer trial evoke Nordisk's Alzheimer's results to be presented at CTAD 2025 Details of failed studies cast

These conditions are not contraindications to semaglutide or tirzepatide use

Phosphorylation meets ubiquitination: the control of NF-kappaB activity

Biolcati G, Marchesini E, Sorge F, Barbieri L, SchneiderYin X, Minder E

the AGE-RAGE signaling, which induces axonal atrophy through p38 MAPK activation (Sango et al., 2025), and the PKC- activation, which impairs nerve blood flow via endothelin-1 overexpression ( Hyperglycemia-induced mitochondrial dysfunction in neuronal and Schwann cells leads to excessive O 2 production at complex I and III of the ETC, which initiates a cascade of injury through four primary mechanisms (Wu L

The August 2025 policy change excludes all weight-related indications

xiv + 727 pp